Cannpal Animal Therapeutics Limited has successfully completed dosing the last treatment group for its Phase 1B Study for CPAT-01, in development as a pain and inflammatory control for dogs; 48 mixed beagles and foxhounds were recruited for the study across various age andweights, with no adverse events reported across all treatment groups; Gene expression study results so far have revealed clear cannabinoid impact inimportant pain and inflammatory pathways supporting the proposed pain andinflammatory control claims for CPAT-01; The Company has commenced its battery of regulatory required toxicology studies in the United States. The results of the first study are on track for confirming thtoxicological safety of CPAT-01; and CannPal has received two ethics approvals to expand the testing of CPAT-01 in felinstudies with over 20 cats recruited and two study sites confirmed.